September 1, 2009

Cardio3 BioSciences Presents Update on C-Cure(R) Second Generation Stem Cell Therapy for Heart Failure at European Society of Cardiology Congress

By Kelley Luckstein

Symposium Session Draws Leading Experts to Review Recent Developments in Cardiac Regenerative Therapies


Cardio3 BioSciences, today provided an update and review of the clinical development of its unique C-Cure(R) therapy at the European Society of Cardiology Congress in Barcelona. A unique second generation stem-cell derived therapy, C-Cure allows the differentiation of a patient's own cells into 'cardiopoietic' cells which grow into new heart cells and repair heart muscle. C-Cure is currently undergoing a randomized, multi-center pivotal trial, designed to evaluate the safety and efficacy beyond optimal clinical care in patients with heart failure, one of the world's largest unmet medical needs.


The update was part of a broader satellite symposium at the Congress led by a panel of expert speakers. In addition to reviewing C-Cure the distinguished panel traced the progress made in the development of regenerative therapies for heart failure from first generation to second generation products.


C-Cure draws on an unrivalled understanding of the fundamental science of heart cell development at the Mayo Clinic and within the Cardio3 BioSciences scientific in-house team.


PRNewswire, 08/31/09

Tags: biosciences, Business Relations, Cardiology, Cardiology

Please sign in or register to post a reply.
Contact Us · Privacy Policy